Aug. 4 at 10:14 AM
$BCYC It’s annoying, but the pipeline is still very promising
It’s just that there is no news in the near future, I hope to see it slowly stick to this
$4
Some good buys recently again from institutions, clearly the price now is mismatched to potential + risk of this stock
No near term dilution, just need 2027 to come faster, the pivotal point is the Phase 2 data from Nuzedatide Pevedotin.
Data initially shared is encouraging, and there is some good signals that it will replicate similarly for Phase 2
If management decided to buy some shares would be really nice
